Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$45.66 USD

45.66
3,584,443

+0.49 (1.08%)

Updated May 14, 2024 04:00 PM ET

After-Market: $45.65 -0.01 (-0.02%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

Value investing is easily one of the most popular ways to find great stocks in any market environment.

    Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer

    Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.

      Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

      Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

        4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017

        Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.

          Merck (MRK) Does Well in 2016: Reasons for Outperformance

          Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.

            Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

            Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

              Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

              Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

                Big Pharma Face Off: Is Merck More Attractive than J&J?

                Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                  Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                  Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

                    The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                    The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                      Tracey Ryniec headshot

                      Is Brexit a Buying Opportunity?

                      Value investors should keep an eye on what is going on in Great Britain right now.

                        Mark Vickery headshot

                        Q2 Earnings Checklist Keeps Rolling Out: BA, CMCSA, GSK & Others

                        After a busy session after the bell yesterday, including strength from Apple, we see another long list of reporting companies this morning.

                          Brian Bolan headshot

                          CDXS and LOGI are Aggressive Growth Stocks

                          Biotech supply chain and computer peripherals are the focus

                            Brian Bolan headshot

                            Bull of the Day: Codexis (CDXS)

                            Think of this stock as the supply chain to big biotech and that is driving huge earnings growth.